Disease-related autoantibody profile in patients with systemic sclerosis

References

• Sakkas LI, Platsoucas CD. Is systemic sclerosis an antigen-driven T cell disease? Arthritis Rheum. 2004;50:1721–1733.
   PubMed Web of Science ®Google Scholar
• Varga J, Abraham D. Systemic sclerosis: a prototypic multisystem fibrotic disorder. J Clin Invest. 2007;117:557–567.
   PubMed Web of Science ®Google Scholar
• Sakkas LI, Bogdanos DP. Systemic sclerosis: new evidence re-enforces the role of B cells. Autoimmun Rev. 2016;15:155–161.
   PubMed Web of Science ®Google Scholar
• Reveille JD, Solomon DH. Evidence-based guidelines for the use of immunologic tests: anticentromere, Scl-70, and nucleolar antibodies. Arthritis Rheum. 2003;49:399–412.
   PubMed Web of Science ®Google Scholar
• Nihtyanova SI, Denton CP. Autoantibodies as predictive tools in systemic sclerosis. Nat Rev Rheumatol. 2010;6:112–116.
   PubMed Web of Science ®Google Scholar
• Steen VD. Autoantibodies in systemic sclerosis. Semin Arthritis Rheum. 2005;35:35–42.
   PubMed Web of Science ®Google Scholar
• Dick T, Mierau R, Sternfeld R, et al. Clinical relevance and HLA association of autoantibodies against the nucleolus organizer region (NOR-90). J Rheumatol. 1995;22:67–72.
   PubMed Web of Science ®Google Scholar
• Baroni SS, Santillo M, Bevilacqua F, et al. Stimulatory autoantibodies to the PDGF receptor in systemic sclerosis. N Engl J Med. 2006;354:2667–2676.
   PubMed Web of Science ®Google Scholar
• Koenig M, Dieude M, Senecal JL. Predictive value of antinuclear autoantibodies: the lessons of the systemic sclerosis autoantibodies. Autoimmun Rev. 2008;7:588–593.
   PubMed Web of Science ®Google Scholar
• Hamaguchi Y. Autoantibody profiles in systemic sclerosis: predictive value for clinical evaluation and prognosis. J Dermatol. 2010;37:42–53.
   PubMed Web of Science ®Google Scholar
• van den Hoogen F, Khanna D, Fransen J, et al. 2013 classification criteria for systemic sclerosis: an American College of Rheumatology/European League against Rheumatism collaborative initiative. Arthritis Rheum. 2013;65:2737–2747.
   PubMed Web of Science ®Google Scholar
• Villalta D, Imbastaro T, Di Giovanni S, et al. Diagnostic accuracy and predictive value of extended autoantibody profile in systemic sclerosis. Autoimmun Rev. 2012;12:114–120.
   PubMed Web of Science ®Google Scholar
• Kuwana M, Kaburaki J, Okano Y, et al. The HLA-DR and DQ genes control the autoimmune response to DNA topoisomerase I in systemic sclerosis (scleroderma). J Clin Invest. 1993;92:1296–1301.
   PubMed Web of Science ®Google Scholar
• Steen V, Domsic RT, Lucas M, et al. A clinical and serologic comparison of African American and Caucasian patients with systemic sclerosis. Arthritis Rheum. 2012;64:2986–2994.
   PubMed Web of Science ®Google Scholar
• Gelber AC, Manno RL, Shah AA, et al. Race and association with disease manifestations and mortality in scleroderma: a 20-year experience at the Johns Hopkins Scleroderma Center and review of the literature. Medicine (Baltimore). 2013;92:191–205.
   PubMed Web of Science ®Google Scholar
• Simonneau G, Gatzoulis MA, Adatia I, et al. Updated clinical classification of pulmonary hypertension. J Am College Cardiol. 2013;62:D34–D41.
   PubMed Web of Science ®Google Scholar
• Vlachoyiannopoulos PG, Dafni UG, Pakas I, et al. Systemic scleroderma in Greece: low mortality and strong linkage with HLA-DRB1*1104 allele. Ann Rheum Dis. 2000;59:359–367.
   PubMed Web of Science ®Google Scholar
• Meier FM, Frommer KW, Dinser R, et al. Update on the profile of the EUSTAR cohort: an analysis of the EULAR scleroderma trials and research group database. Ann Rheum Dis. 2012;71:1355–1360.
   PubMed Web of Science ®Google Scholar
• Hudson M, Mahler M, Pope J, et al. Clinical correlates of CENP-A and CENP-B antibodies in a large cohort of patients with systemic sclerosis. J Rheumatol. 2012;39:787–794.
   PubMed Web of Science ®Google Scholar
• Chang WS, Schollum J, White DH, et al. A cross-sectional study of autoantibody profiles in the Waikato systemic sclerosis cohort, New Zealand. Clin Rheumatol. 2015;34:1921–1927.
   PubMed Web of Science ®Google Scholar
• Mehra S, Walker J, Patterson K, et al. Autoantibodies in systemic sclerosis. Autoimmun Rev. 2013;12:340–354.
   PubMed Web of Science ®Google Scholar
• Graf SW, Hakendorf P, Lester S, et al. South Australian Scleroderma Register: autoantibodies as predictive biomarkers of phenotype and outcome. Int J Rheum Dis. 2012;15:102–109.
   PubMed Web of Science ®Google Scholar
• Mehta H, Goulet PO, Nguyen V, et al. Topoisomerase I peptide-loaded dendritic cells induce autoantibody response as well as skin and lung fibrosis. Autoimmunity. 2016;49:503–513.
   PubMed Web of Science ®Google Scholar
• Walker UA, Tyndall A, Czirjak L, et al. Geographical variation of disease manifestations in systemic sclerosis: a report from the EULAR Scleroderma Trials and Research (EUSTAR) group database. Ann Rheum Dis. 2009;68:856–862.
   PubMed Web of Science ®Google Scholar
• Walker UA, Tyndall A, Czirjak L, et al. Clinical risk assessment of organ manifestations in systemic sclerosis: a report from the EULAR scleroderma trials and research group database. Ann Rheum Dis. 2007;66:754–763.
   PubMed Web of Science ®Google Scholar
• Sunderkotter C, Herrgott I, Bruckner C, et al. Comparison of patients with and without digital ulcers in systemic sclerosis: detection of possible risk factors. Br J Dermatol. 2009;160:835–843.
   PubMed Web of Science ®Google Scholar
• Launay D, Humbert M, Berezne A, et al. Clinical characteristics and survival in systemic sclerosis-related pulmonary hypertension associated with interstitial lung disease. Chest. 2011;140:1016–1024.
   PubMed Web of Science ®Google Scholar
• Lefevre G, Dauchet L, Hachulla E, et al. Survival and prognostic factors in systemic sclerosis-associated pulmonary hypertension: a systematic review and meta-analysis. Arthritis Rheum. 2013;65:2412–2423.
   PubMed Web of Science ®Google Scholar
• Le Pavec J, Girgis RE, Lechtzin N, et al. Systemic sclerosis-related pulmonary hypertension associated with interstitial lung disease: impact of pulmonary arterial hypertension therapies. Arthritis Rheum. 2011;63:2456–2464.
   PubMed Web of Science ®Google Scholar
• Mahler M, Maes L, Blockmans D, et al. Clinical and serological evaluation of a novel CENP-A peptide based ELISA. Arthritis Res Ther. 2010;12:R99.
   PubMed Web of Science ®Google Scholar
• Low AH, Wong S, Thumboo J, et al. Evaluation of a new multi-parallel line immunoassay for systemic sclerosis-associated antibodies in an Asian population. Rheumatology (Oxford). 2012;51:1465–1470.
   PubMed Web of Science ®Google Scholar
• Peterson LK, Jaskowski TD, Mayes MD, et al. Detection of anti-U3-RNP/fibrillarin IgG antibodies by line immunoblot assay has comparable clinical significance to immunoprecipitation testing in systemic sclerosis. Immunol Res. 2016;64:483–488.
   PubMed Web of Science ®Google Scholar
• Patterson KA, Roberts-Thomson PJ, Lester S, et al. Interpretation of an extended autoantibody profile in a well-characterized australian systemic sclerosis (Scleroderma) cohort using principal components analysis. Arthritis Rheumatol. 2015;67:3234–3244.
   PubMed Web of Science ®Google Scholar
• Domsic RT, Medsger TA Jr. Autoantibodies and their role in scleroderma clinical care. Curr Treat Opt Rheum. 2016;2:239–251.
   Google Scholar
• Sobanski V, Dauchet L, Lefevre G, et al. Prevalence of anti-RNA polymerase III antibodies in systemic sclerosis: New data from a French cohort and a systematic review and meta-analysis. Arthritis Rheumatol. 2014;66:407–417.
   PubMed Web of Science ®Google Scholar
• Bunn CC, Denton CP, Shi-Wen X, et al. Anti-RNA polymerases and other autoantibody specificities in systemic sclerosis. Br J Rheumatol. 1998;37:15–20.
   PubMedGoogle Scholar
• Wodkowski M, Hudson M, Proudman S, et al. Clinical correlates of monospecific anti-PM75 and anti-PM100 antibodies in a tri-nation cohort of 1574 systemic sclerosis subjects. Autoimmunity. 2015;48:542–551.
   PubMed Web of Science ®Google Scholar
• Aggarwal R, Lucas M, Fertig N, et al. Anti-U3 RNP autoantibodies in systemic sclerosis. Arthritis Rheum. 2009;60:1112–1118.
   PubMed Web of Science ®Google Scholar
• Pollard KM, Pearson DL, Bluthner M, et al. Proteolytic cleavage of a self-antigen following xenobiotic-induced cell death produces a fragment with novel immunogenic properties. J Immunol. 2000;165:2263–2270.
   PubMed Web of Science ®Google Scholar
• Luchetti MM, Moroncini G, Escamez MJ, et al. Induction of scleroderma fibrosis in skin-humanized mice by anti-platelet-derived growth factor receptor agonistic autoantibodies. Arthritis Rheumatol. 2016;68:2263–2273.
   PubMed Web of Science ®Google Scholar
• Rozman B, Cucnik S, Sodin-Semrl S, et al. Prevalence and clinical associations of anti-Ku antibodies in patients with systemic sclerosis: a European EUSTAR-initiated multi-centre case-control study. Ann Rheum Dis. 2008;67:1282–1286.
   PubMed Web of Science ®Google Scholar
• Hoa S, Hudson M, Troyanov Y, et al. Single-specificity anti-Ku antibodies in an international cohort of 2140 systemic sclerosis subjects: clinical associations. Medicine (Baltimore). 2016;95:e4713.
   PubMed Web of Science ®Google Scholar
• Lakota K, Thallinger GG, Sodin-Semrl S, et al. International cohort study of 73 anti-Ku-positive patients: association of p70/p80 anti-Ku antibodies with joint/bone features and differentiation of disease populations by using principal-components analysis. Arthritis Res Ther. 2012;14:R2.
   PubMed Web of Science ®Google Scholar
• Boubnov NV, Hall KT, Wills Z, et al. Complementation of the ionizing radiation sensitivity, DNA end binding, and V(D)J recombination defects of double-strand break repair mutants by the p86 Ku autoantigen. Proc Natl Acad Sci USA. 1995;92:890–894.
   PubMed Web of Science ®Google Scholar
• Belizna C, Henrion D, Beucher A, et al. Anti-Ku antibodies: clinical, genetic and diagnostic insights. Autoimmun Rev. 2010;9:691–694.
   PubMed Web of Science ®Google Scholar
• Hanke K, Bruckner CS, Dahnrich C, et al. Antibodies against PM/Scl-75 and PM/Scl-100 are independent markers for different subsets of systemic sclerosis patients. Arthrit Res Ther. 2009;11:R22.
   PubMed Web of Science ®Google Scholar
• Muro Y, Hosono Y, Sugiura K, et al. Anti-PM/Scl antibodies are found in Japanese patients with various systemic autoimmune conditions besides myositis and scleroderma. Arthritis Res Ther. 2015;17:57.
   PubMed Web of Science ®Google Scholar
• Wodkowski M, Hudson M, Proudman S, et al. Monospecific anti-Ro52/TRIM21 antibodies in a tri-nation cohort of 1574 systemic sclerosis subjects: evidence of an association with interstitial lung disease and worse survival. Clin Exp Rheumatol. 2015;33(4 Suppl 91):S131–S135.
   Web of Science ®Google Scholar